Logo

BMS Reports sNDA Accpetance with Priority Review by the US FDA for Augtyro to Treat Solid Tumors

Share this
BMS

BMS Reports sNDA Accpetance with Priority Review by the US FDA for Augtyro to Treat Solid Tumors

Shots:

  • The US FDA has accepted BMS’ sNDA for Augtyro (repotrectinib) to treat patients with NTRK+ locally advanced or metastatic solid tumors where surgical removal can lead to severe morbidity. The decision is expected in Jun 2024
  • The acceptance was based on results from the two P-I/II (TRIDENT-1 & CARE) studies assessing Augtyro’s safety, tolerability, PK and anti-tumor activity in adult and pediatric patients (12yrs. & older) with NTRK+ locally advanced or metastatic solid tumors
  • Results from the TRIDENT-1 trial revealed favorable response rates in NTRK+ solid tumor patients, with strong DoR and intracranial responses. The study is in progress for further evaluation. The CARE study supported these results

Ref: BMS | Image: BMS

Related News:- BMS Reports the Acceptance of its sBLA for Opdivo Combination Therapy by the US FDA and EMA for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions